Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Acute febrile rash (exanthem): when are tests needed? Measles, Kawasaki disease, drug eruption, primary HIV infection

Dermatology · Symptom or situation · updated 2026-11-08

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Situation with multiple causes: for measles alone, 873 cases notified in France in 2025 (1.1 per 100 000 inhabitants, imported cases excluded) out of 1 176 suspected cases [1]. No overall frequency of acute febrile rashes found.

Suspected measles: confirm and notify without delay

Laboratory confirmation

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Suspected Kawasaki disease: refer the same day

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Rash on medication: look for a severe cutaneous drug reaction

Suspected DRESS (fever, facial oedema, lymphadenopathy): stop the drug and arrange hospital admission the same day; if these tests are done in the community, they must not delay admission

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Adolescent or adult: febrile exanthem with lymphadenopathy or ulcers (primary HIV infection?)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Typical viral exanthem in a child in good general condition

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Sources (24)
  1. Santé publique France. Rougeole : bilan annuel de la surveillance, année 2025. Bulletin national, 18 mai 2026.
  2. Direction générale de la santé. DGS-Urgent n° 2025_08 du 7 mars 2025 : vigilance renforcée dans le cadre de la recrudescence de la rougeole en France (diffusé par l'ARS Grand Est).
  3. Santé publique France. Rougeole : notre action (critères de signalement et définition des cas). Page consultée le 11 octobre 2026.
  4. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 5270 (ARN du virus de la rougeole), 1768-1770 (sérologie rougeole) et 4122 (charge virale VIH).
  5. UK Health Security Agency. National measles guidelines, version 8, juillet 2026.
  6. Robert Koch-Institut. RKI-Ratgeber Masern, version du 14 novembre 2024.
  7. Gregory DS, Shah SS, England BL. Measles: Rapid Evidence Review. Am Fam Physician. 2026;114(4), publié en ligne le 15 octobre 2026.
  8. National Institute for Health and Care Excellence. Fever in under 5s: assessment and initial management. NICE guideline NG143, 7 novembre 2019, mise à jour du 26 novembre 2021 (recommandations 1.2.25 à 1.2.27, tableau 2).
  9. Marchesi A, Rigante D, Cimaz R, Ravelli A, Tarissi de Jacobis I, Rimini A, et al. Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. Ital J Pediatr. 2021;47(1):16.
  10. Centre de référence des maladies auto-inflammatoires et de l'amylose inflammatoire (CeRéMAIA), filière FAI2R, Haute Autorité de santé. Maladie de Kawasaki. Synthèse à destination du médecin traitant, extraite du PNDS, septembre 2022.
  11. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135:e927-99.
  12. Darby JB, Jackson JM. Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison. Am Fam Physician. 2021;104(3):244-252.
  13. The Royal Children's Hospital Melbourne. Kawasaki disease. Clinical Practice Guideline (approuvé par le Paediatric Improvement Collaborative), mise à jour de janvier 2026.
  14. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071-80.
  15. Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Haute Autorité de santé. Nécrolyse épidermique de l'adulte (syndromes de Stevens-Johnson et de Lyell). Synthèse à destination du médecin traitant, extraite du PNDS, novembre 2023.
  16. Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, groupe Toxidermies de la Société française de dermatologie. Protocole national de diagnostic et de soins (PNDS) : DRESS de l'adulte et de l'enfant, 2024 (publié par la HAS en novembre 2024).
  17. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Clinical guideline CG183, 3 septembre 2014.
  18. Usatine RP, Sandy N. Dermatologic Emergencies. Am Fam Physician. 2010;82(7):773-780.
  19. Cabañas R, Ramírez E, Sendagorta E, et al. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-253.
  20. Palfreeman A, Sullivan A, Rayment M, et al. British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020. HIV Med 2020;21(Suppl 6):1-26.
  21. Goldschmidt R, Chu C. HIV Infection in Adults: Initial Management. Am Fam Physician. 2021;103(7):407-416.
  22. Filière MCGRE. Protocole national de diagnostic et de soins (PNDS) : syndromes drépanocytaires majeurs de l'enfant et de l'adolescent, mars 2024 (HAS, mai 2024).
  23. Servey JT, Reamy BV, Hodge J. Clinical Presentations of Parvovirus B19 Infection. Am Fam Physician. 2007;75(3):373-376.
  24. Saguil A, Kane SF, Lauters R, Mercado MG. Hand-Foot-and-Mouth Disease: Rapid Evidence Review. Am Fam Physician. 2019;100(7):408-414.